SCHEMBL6147569

SCHEMBL6147569

CCCCC[C@H](C(=O)O)c1ccc2c(c1)C(C)(C)CCO2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RARA P10276 4/20 0.45
RARB P10826 4/20 0.45
RARG P13631 4/20 0.45
CYP26A1 O43174 1/20 0.43
CYP26B1 Q9NR63 1/20 0.43
RXRA P19793 5/20 0.41
HNF4A P41235 2/20 0.41
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
SSTR5 P35346 2/20 0.36
AKR1B1 P15121 1/20 0.36
MAPK9 P45984 1/20 0.36
UGCG Q16739 3/20 0.35
RXRB P28702 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6147566 1.00 RARA (0.45) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6147567 1.00 RARA (0.45) RARARARBRARGCYP26A1CYP26B1
SCHEMBL4849371 0.91 RXRA (0.41) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6144484 0.86 PTGS1 (0.36) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6144637 0.83 RXRA (0.48) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6146627 0.83 RXRA (0.48) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6143928 0.83 RXRA (0.50) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6146933 0.83 RXRA (0.50) RARARARBRARGCYP26A1CYP26B1
SCHEMBL6143925 0.83 RXRA (0.50) RARARARBRARGCYP26A1CYP26B1
SCHEMBL7076116 0.82 PTGS1 (0.33) RARARARBRARGPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1293034-C New gamma selective retinoids HOFFMANN LA ROCHE (CH) 2007-01-03 CN disclosed
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
CN-1430596-A New gamma selective retinoids HOFFMANN LA ROCHE (CH) 2003-07-16 CN disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB RARA 1/4885RARB 3/4885RARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.